MRM vs TSLA
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
MRM presents a high-risk profile characterized by a Piotroski F-Score of 4/9 (Stable) but severe underlying liquidity distress. While the stock trades below its Graham Number ($1.27) and Intrinsic Value ($2.59), these valuation metrics are overshadowed by a catastrophic Current Ratio of 0.24 and an extreme Debt/Equity ratio of 7.86. The company is experiencing declining revenue growth (-6.70%) and deep operating losses (-25.84% margin), suggesting that the nominal net profit is likely driven by non-operating items rather than core business health.
Tesla's deterministic health is stable with a Piotroski F-Score of 4/9, but its valuation is fundamentally disconnected from current performance. The Graham Number ($22.85) and Intrinsic Value ($7.42) indicate extreme overvaluation relative to the current price of $343.25. With negative YoY revenue growth (-3.10%) and a collapse in earnings growth (-60.60%), the P/E ratio of 323.82 is unsustainable. Technical trends and insider activity are both strongly bearish, suggesting a significant correction is likely.
Compare Another Pair
Related Comparisons
MRM vs TSLA: Head-to-Head Comparison
This page compares MEDIROM Healthcare Technologies Inc. (MRM) and Tesla, Inc. (TSLA) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.